Liquid biopsy as a follow-up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors

Cancer. 2020 Jan 1;126(1):22-25. doi: 10.1002/cncr.32482. Epub 2019 Sep 10.
No abstract available

Keywords: EGFR mutations; NGS; NSCLC; liquid biopsy; real-time monitoring.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cell-Free Nucleic Acids*
  • ErbB Receptors
  • Follow-Up Studies
  • Liquid Biopsy
  • Protein Kinase Inhibitors*

Substances

  • Cell-Free Nucleic Acids
  • Protein Kinase Inhibitors
  • ErbB Receptors